The ratio of pseudophakic:phakic eyes was 29:8, respectively. Baseline mean BCVA was 38.1±2.8 (mean ± standard error [SE]) letters improved to 47.2±3.5 letters (P=0.001) at 12 months. BCVA was improved or maintained in 84.8% eyes, and 42.4% gained ≥15 letters, and 63.4% eyes gained ≥10 letters from baseline. The percentage of eyes achieved ≥70 ETDRS was 12% from baseline at 12 months. Mean CRT decreased by -220.2±32.1 μm from baseline to 330.9±32.5 μm at 12 months (P=0.001). At baseline 27.3% of patients were being treated with IOP-lowering medication. At last observation 54.5% eyes were being managed with IOP lowering medication.

Conclusions:

Real-life outcomes show that the funtional and the anatomical improvements achieved with ILUVIEN implant were maintained up to 12 months with minimal need of top-up therapy. IOP a know class effect of steroids was manageable with combination therapy. These results demonstrate that ILUVIEN is an effective long-term option in treating chronic DME.